Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IDT Australia Limited ( (AU:IDT) ) has issued an announcement.
IDT Australia Limited reported a 41% increase in revenue for FY25, reaching $20 million, marking the successful completion of the first stage of its strategic transformation program, the ‘Rebuild Strategy’. The company experienced significant growth in its Advanced Therapies vertical, with revenue surging 361% due to high demand for ADCs and mRNA technologies. Despite a net loss of $8.1 million, IDT is focusing on achieving positive cash flow and profitability in the next phase of its transformation, the ‘Sustainability Strategy’. The company aims to leverage its robust sales pipeline and recent contract wins to drive future growth.
More about IDT Australia Limited
IDT Australia Limited is an Australian pharmaceutical manufacturing company based in Boronia, Victoria. It specializes in the development and production of high potency and high containment pharmaceutical products for both local and international clients. The company’s facilities are cGMP compliant and regularly audited by the US FDA and Australian TGA. IDT offers comprehensive services in new drug development, scale-up, commercial active drug manufacture, and various oral and injectable finished drug dose forms.
Average Trading Volume: 221,396
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$28.47M
For a thorough assessment of IDT stock, go to TipRanks’ Stock Analysis page.